Drug intelligence / Profile preview

CJ-40010 CVA16 vaccine

Development stage: Unknown
Modality: Vaccines & Immunotherapeutics

Overview

CJ-40010 CVA16 vaccine is an inactivated whole-virus vaccine candidate developed to prevent Hand, Foot, and Mouth Disease (HFMD) caused by Coxsackievirus A16 (CVA16). CVA16 is a major pathogen responsible for HFMD, particularly in young children. The vaccine works by introducing inactivated CVA16 viral antigens to the immune system, stimulating the production of neutralizing antibodies that can recognize and neutralize the live virus, thereby conferring protective immunity. This vaccine candidate has been evaluated in animal models and has progressed to Phase 1 clinical trials to assess its safety and immunogenicity in healthy subjects.

Other names: CVA16 vaccineCVA-16 vaccineCVA 16 vaccine

Targets

EV (Enterovirus)

Beyond the preview

Go deeper on CJ-40010 CVA16 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CJ-40010 CVA16 vaccine.

Explore the full profile